Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
saRNAs | 4 |
Top 5 Target | Count |
---|---|
STING(Stimulator of interferon genes) | 1 |
Target |
Mechanism CEBPA stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
C1-INH(MiNA Therapeutics) | Autoimmune Diseases More | Preclinical |
HbF(MiNA Therapeutics) | Beta-Thalassemia More | Preclinical |
MTL-STING ( STING ) | Solid tumor More | Preclinical |
saRNA therapeutics (MiNA Therapeutics/Boehringer Ingelheim) | Nonalcoholic Steatohepatitis More | Discovery |
MTL-301 | Diabetes Mellitus, Type 1 More | Pending |